Responses
Regular and Young Investigator Award Abstracts
Regulatory, Financial and Access Considerations
1431 Developing an FDA-qualified drug development tool, the membrane proteome array, for specificity testing of antibodies and CAR-T cell therapies
Compose a Response to This Article
Other responses
No responses have been published for this article.
